Head, Gray School of Medical Sciences, Gray Faculty of Medical & Health Sciences
Sagol School of Neuroscience, School of Biomedical Engineering, Tel Aviv University
Israel
Group Website: www.satchifainarolab.com
Ronit Satchi-Fainaro is a Professor at Tel Aviv University, where she is Head, Gray School of Medical Sciences; Head, Cancer Research & Nanomedicine Laboratory; Director, Cancer Biology Research Center; Director, TAU Kahn 3D-BioPrinting Initiative; and holds the Lion Chair in Nanosciences. She received her BPharm from the Hebrew University in Jerusalem and her PhD from UCL, followed by a Postdoc at Harvard University and Children’s Hospital Boston. She serves on the BoD of Teva Pharmaceutical Industries, is a SAB member of the CAS, U. Lisbon, VHIR, several VCs, and editorial boards. She has published 180 papers, is an inventor on 95 patents, has founded 3 spin-offs, and has initiated 2 clinical trials. Utilizing 4D-bioprinted cancer models, mouse models of primary and metastatic cancers, and clinical data from patients with metastatic disease, her work uncovers the mechanisms underlying tumor progression, providing a mechanistic basis for therapeutic targeting to prevent recurrence and metastatic relapse. She was awarded numerous prestigious grants and prizes, among them Fulbright, Rothschild, EACR Young Investigator Award, Juludan Prize, Teva Pharmaceutical Industries Founders Award, CRS Samyang Award, Youdim Family Prize for Excellence in Cancer Research, Kadar Family Award for Outstanding Research, Michael Bruno Memorial Award, Humboldt Foundation Bessel Research Prize, Salisbury Award for Entrepreneurial Translational Research, and Tenne Family Prize for Nanoscale Sciences. She was elected an AIMBE Fellow and to the CRS College of Fellows. Her scientific achievements were acknowledged numerous times through inclusion in honorary lists by leading magazines (Forbes Power Women List, Globes Woman of the Year, and Israel’s Top 40 under 40 by The Marker). She represented Israel at the Biennale in Venice, built an installation on the Influence of Medicine on Architecture, and received 4 La Caixa Bank Foundation grants, ERC Consolidator, ERC Advanced, 2 ERC PoC, and EIC Grants.
Representative Publications
[1] Laue, Pozzi, et al., p53 inactivation drives breast cancer metastasis to the brain through SCD1 upregulation and increased fatty acid metabolism. Nature Genetics 2026 Jan;58(1):116-131
[2] Koshrovski-Michael, et al., Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin-expressing cancers. Science Advances 2024 Dec 13;10(50):eadr4762.
[3] Israeli Dangoor, et al., CCL2 blockade combined with PD-1/P-selectin immunomodulators impedes breast cancer brain metastasis. Brain. 2025 May 13;148(5):1740-1756.
[4] Acúrcio, Kleiner, Vaskovich-Koubi, et al., Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy. Advanced Science. 2024 Oct;11(40):e2404159.
[5] Neufeld, Yeini, Pozzi, Satchi-Fainaro R. 3D bioprinted cancer models: from basic biology to drug development. Nature Reviews Cancer. 2022 Dec;22(12):679-692.
[6] Neufeld, et al., Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment. Science Advances. 2021 Aug 18;7(34):eabi9119.
[7] Yeini, et al., P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression. Nat Commun. 2021 Mar 26;12(1):1912.
[8] Conniot, Scomparin, et al., Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nature Nanotechnology. 2019 Sep;14(9):891-901.
